Why the study?
Does myeloid-specific catalase over-expression improve post-infarct healing and cardiac function following myocardial infarction?
Does myeloid-specific catalase over-expression improve post-infarct healing and cardiac function following myocardial infarction?
Myeloid-specific catalase over-expression provides acute functional benefits post-myocardial infarction but lacks chronic benefits due to increased fibrosis, highlighting the need for temporal and cell-specific delivery.
Acute post-MI gains from myeloid catalase overexpression fail to persist; leaves open timed, cell-specific delivery to balance fibrosis and repair.
Cardiovascular disease is the leading cause of death in the United States and new treatment options are greatly needed. Oxidative stress is increased following myocardial infarction and levels of antioxidants decrease, causing imbalance that leads to dysfunction. Therapy involving catalase, the endogenous scavenger of hydrogen peroxide (H2O2), has been met with mixed results. When over-expressed in cardiomyocytes from birth, catalase improves function following injury. When expressed in the same cells in an inducible manner, catalase showed a time-dependent response with no acute benefit, but a chronic benefit due to altered remodeling. In myeloid cells, catalase over-expression reduced angiogenesis during hindlimb ischemia and prevented monocyte migration. In the present study, due to the large inflammatory response following infarction, we examined myeloid-specific catalase over-expression on post-infarct healing. We found a significant increase in catalase levels following infarction that led to a decrease in H2O2 levels, leading to improved acute function. This increase in function could be attributed to reduced infarct size and improved angiogenesis. Despite these initial improvements, there was no improvement in chronic function, likely due to increased fibrosis. These data combined with what has been previously shown underscore the need for temporal, cell-specific catalase delivery as a potential therapeutic option.
No takes yet. Share an insight, caveat, or question.
Cabigas et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: